Search This Blog

Monday, November 3, 2025

Neurocrine Goes to China To Grow Pipeline in up to $881M TransThera Deal

 

At the center of the licensing deal is an NLRP3 inhibitor that has shown “encouraging efficacy in acute inflammation models,” according to TransThera, indicating its potential in various metabolic and inflammatory diseases.

Neurocrine is joining the gold rush of companies finding assets in China, licensing an NLRP3 inhibitor in a deal with the Nanjing-based TransThera Sciences.

Under the terms of the agreement, TransThera will receive an upfront payment along with R&D and sales milestones that could total $881.5 million, the company revealed in a press release Monday.

The deal gives Neurocrine rights outside of greater China—including mainland China, Hong Kong, Taiwain and Macao—to TransThera’s portfolio of NLRP3 inhibitors. While the company’s pipeline only lists one candidate, called TT-02332, in that portfolio, TransThera’s release suggests more than one molecule available for licensing.

Under the terms of the deal, Neurocrine and TransThera will develop NLRP3 inhibitors for “multiple diseases.” What specific indications could be targeted using the molecule or molecules were not revealed. However, TransThera said, “TT-02332 has shown encouraging efficacy in acute inflammation models, indicating its potential application in various metabolic and inflammatory diseases.”

NLRP3 proteins are involved in the inflammasome, an innate cellular response to infection that promotes inflammation. Overactive activation of proteins in the inflammasome pathway are implicated in a number of diseases, including diabetes, atherosclerosis and Alzheimer’s disease.

Neurocrine is on the upswing, recently announcing total sales of $790 million for the third quarter of 2025, a 28% year-over-year growth. However, the company is relying almost exclusively on one asset and might be looking to broaden its pipeline. In Q3, $687 million of its Neurocrine’s income came from sales of Ingrezza, its treatment for the movement disorder tardive dyskinesia, as well as chorea associated with Huntington’s disease.

Rounding out Neurocrine’s sales was Crenessity, its treatment for congenital adrenal hyperplasia, which reeled in $98 million.

Neurocrine made another move to diversify its assets earlier this year, grabbing the depression treatment osavampator from its long-term partner Takeda. That molecule scored a major win in a Phase II trial in 2024, significantly easing symptoms of major depressive disorder in comparison to placebo.

https://www.biospace.com/deals/neurocrine-goes-to-china-to-grow-pipeline-in-up-to-881m-transthera-deal

Trump Admin Will Partially Fund November Food Stamps: Filing

 by Zachary Stieber via The Epoch Times (emphasis ours),

The U.S. Department of Agriculture (USDA) will fund food stamps for November at reduced levels, Trump administration officials said on Nov. 3.

A woman walks by a sign advertising the acceptance of food stamps, in Miami, Fla., on Oct. 31, 2025. Joe Raedle/Getty Images

The USDA will spend billions of dollars in contingency funds, but will not use any additional money, administration lawyers said in a court filing.

That means many SNAP recipients will only receive half as much in benefits as they usually do, the lawyers said.

The government met its deadline of 12 p.m. on Monday to give an update on funding the federal food stamp program, known as SNAP, for November.

U.S. District Judge Jack McConnell previously ruled that the USDA had to at least partially fund the November benefits by using contingency money allocated in federal law “as may become necessary to carry out program operations.”

“Because of the lack of appropriations for Fiscal Year 2026 (i.e., ’the shutdown'), use of those contingency funds has now become required because available funding is necessary to carry out the program operations, i.e., to pay citizens their SNAP benefits,” McConnell said in a Nov. 1 order.

Congress allocated $6 billion in contingency funds, but nearly $1 billion has already been spent, administration officials have said. Officials had resisted using the contingency money, saying it was unavailable because there was no more underlying funding for SNAP in place due to the government shutdown that started on Oct. 1. Congress has not yet reached a deal to reopen the government or provide new funding for SNAP.

McConnell ordered officials to fund SNAP from the bench during a hearing on Friday. President Donald Trump later on Friday said that he directed White House lawyers to seek clarification on how the administration could keep funding SNAP.

SNAP payments were suspended on Nov. 1 as that unfolded.

It costs about $9 billion to fund SNAP each month. SNAP pays an average of $187.20 a month to electronic cards for about 42 million people, according to the USDA.

McConnell suggested Saturday that officials should “find the additional funds necessary (beyond the contingency funds) to fully fund the November SNAP payments.” They could draw from a tranche of more than $23 billion that came from tariffs, he said.

If officials choose to fully fund November payments, they must do so by the end of Nov. 3, he said; however, if officials choose not to fully fund the November benefits, they are to use the total remaining contingency funds to make a partial payment by Nov. 5.

In the new filings, officials said that they recently paid $450 million in contingency funds to states for SNAP administrative expenses and $300 million for unrelated grants. They said that they will pay another $450 million for SNAP operations and an additional $150 million for the Nutrition Assistance Program grants.

That leaves $4.6 billion in contingency money for November SNAP benefits, which “will all be obligated to cover 50% of eligible households’ current allotments,” Patrick Penn, a USDA official, said in a declaration to the court.

People whose SNAP applications are verified in November will not receive any money, according to the document.

The USDA is preparing to notify states of the update on Nov. 3, which will prompt states to calculate how much in benefits each household will receive, Penn said.

States will likely have difficulty distributing the reduced SNAP benefits, he said.

“For at least some States, USDA’s understanding is that the system changes States must implement to provide the reduced benefit amounts will take anywhere from a few weeks to up to several months,” he said.

Officials said they opted not to use tariff revenue or additional money because those funds are required for child nutrition efforts and other programs.

https://www.zerohedge.com/political/trump-admin-will-partially-fund-november-food-stamps-filing

EU pledges emergency energy support for Ukraine

 European Commission President Ursula Von der Leyen declared on Monday Brussels' support for Ukraine during the upcoming winter, announcing that the EU would provide emergency energy support to the war-torn country.

"At the same time, we are working on options to ensure the necessary sustained financial assistance to Ukraine. Tomorrow, we will adopt our Enlargement Package, which will commend Ukraine’s remarkable commitment to its European path over the past year. The Commission’s message is clear: Ukraine is ready to move forward," she wrote on X.

Similarly, NATO also said it would help Ukraine "get through" the winter, amid the country's ongoing conflict with Russia.

https://breakingthenews.net/Article/EU-pledges-emergency-energy-support-for-Ukraine/65107437

Kimberly-Clark Biggest Loss Since 'Black Monday' After Unveiling $40 B Kenvue Merger

 Update (1405ET):

Kimberly-Clark shares remain down around 14.5% in late-afternoon trading.  If the losses hold into the close, it would mark the company's steepest one-day drop since October 16, 1987, or just days before the Black Monday crash on October 19, 1987. Earlier, the Kleenex maker unveiled plans to acquire Tylenol producer Kenvue in a $48.7 billion cash-and-stock deal. The announcement sent Kenvue soaring, up 20%. 

Shares of Kimberly-Clark are at their lowest point since late 2019. 

Wall Street analysts are divided on the proposed merger between Kimberly-Clark and Kenvue. Some expect short-term pressure on the stock, while others praised the merger as "strategically transformative"...

Commentary from Wall Street desks (courtsey of Bloomberg):

RBC Capital (Nik Modi)

  • Says the deal is strategically transformative for Kimberly-Clark in the long run as it adds significant positive diversification to its business mix

  • "We believe it will take investors some time to process the long-term implications and would expect KMB shares to come under pressure today and likely trade sideways until investors get more context around recent KVUE regulation/litigation headlines as well as confidence that Kimberly-Clark can turn Kenvue's business around"

Vital Knowledge (Adam Crisafulli)

  • "KVUE brings some iconic brands into the KMB umbrella, and the ~$21/shr purchase price isn't extremely expensive (this only gets KVUE back to where it was trading in Sept.), especially considering ~$2B in synergies, but KMB investors will be wary of the deal given the mounting legal risks facing Tylenol"

  • Says the consumer staples industry has struggled for several quarters due to macro pressures. KVUE has experienced particular strain given company-specific challenges, such as management turnover and scrutiny from the White House

Bloomberg Intelligence (Diana Gomes)

  • Says Kimberly-Clark's cash-and-stock offer for Kenvue reinforces the view that any recovery in Kenvue sales is based on an aggressive step-up in investment, which would act as a further drag on mid-term profit

  • "Another Kenvue organic sales miss in 3Q and lack of overlap in over-the-counter and beauty limits realization of synergies, pegged at 8% to combined operating expenses" 

 *   *   * 

Consumer products company Kimberly-Clark Corporation announced it will acquire Tylenol maker Kenvue in a cash-and-stock transaction valued at nearly $49 billion, marking one of the largest consumer health mergers in history. 

Kimberly-Clark revealed in a press release that the deal values Kenvue at 14.3x its latest twelve months (LTM) adjusted EBITDA. In return, Kenvue shareholders will receive $3.50 in cash and .14625 Kimberly-Clark shares per Kenvue share, for a total of about $ 21.01 per share. The deal is valued at $48.7 billion. 

The deal is expected to close in 2H 2026. Upon completion, Kimberly-Clark shareholders will own 54% of the combined company, while Kenvue shareholders will own 46%. Both boards have unanimously approved the acquisition. JPMorgan Chase is providing committed financing for the deal. 

The merger unites two mega consumer-product giants, creating a global health and wellness powerhouse with top brands, including Kleenex, Huggies, Tylenol, Neutrogena, Listerine, and Band-Aid, that reach consumers worldwide

Here's the justification for the merger:

  • Combines Kimberly-Clark's commercial execution and digital marketing capabilities with Kenvue's science-backed innovation and healthcare professional networks.

  • Expands global footprint across key growth categories in personal care and health.

  • Enhanced R&D and quality investments to accelerate product innovation and address evolving consumer health needs.

  • Kimberly-Clark CEO Mike Hsu will continue leading the merged company, supported by senior executives from both firms.

Based on Kimberly-Clark's current projections, the merger would generate 2025 annual net revenues of about $32 billion and adjusted EBITDA of about $7 billion

All sounds great, but this comes at a time when Tylenol faces political scrutiny via the Trump administration, warning mothers to avoid giving their newborns acetaminophen.

Related:

In markets, Kimberly-Clark shares tumbled 15%, while Kenvue shares jumped 20%. 

The question now is whether government regulators will approve the deal, especially given President Trump's recent comments surrounding Tylenol.

https://www.zerohedge.com/markets/kimberly-clark-acquire-tylenolmaker-kenvue-giant-40-billion-merger

700,000 Ineligible SNAP Recipients Purged After USDA Uncovers Widespread Food Stamp Fraud

 U.S. Secretary of Agriculture Brooke Rollins joined Fox News on Sunday and addressed the American people about the USDA's massive effort to combat fraud in the Supplemental Nutrition Assistance Program (SNAP). 

Rollins said that the Trump administration sent letters to all governors prohibiting illegal aliens from accessing benefits, with a historic request for state data to be audited alongside the Department of Government Efficiency (DOGE). She said only 29 states cooperated, primarily red and some blue states.

She said her team and DOGE found some of the most shocking fraud ever, resulting in the purging of 700,000 ineligible recipients since the president's inauguration, and arrested 118 individuals. 

Some of the key findings she unveiled in the interview:

  • SNAP spending surged nearly 40% under Biden, linked to $100 billion in expenditures.

  • Thousands of ineligible illegals used EBT cards; one individual claimed benefits in six states.

  • About 5,000 deceased recipients were still receiving aid.

Political activist Mike Netter noted on X, "These states are stonewalling because they know the fraud is massive. When you hide the books, it's never to protect the honest folks—it's to cover up the rot. Meanwhile, the states that did cooperate are already exposing exactly the kind of abuse the left swears doesn't exist." 

Rollins called for major reforms to ensure food stamps reach truly vulnerable Americans, not illegal aliens who abuse the system and act as a net drain on public resources.

Also on Sunday, Benny Johnson told Newsmax's Rob Finnerty in a video posted on X (see here) that if tens of millions of Americans were willing to stand in line for an experimental Covid vaccine, they can just as well stand in line for to reapply for food stamps.

"My thought is shut it all down. Force everyone to reapply with American citizenship. Crack down on what is available on these programs - take the junk food off - and you'll see the number of people applying for these programs collapse. Force them to cook their own food," Johnson told Finnerty.

Finnerty responded, "They forced people like sheep to get in line to take vaccines - and within two months - something like 67% of the country was vaccinated - hundreds of millions of people in a short amount of time. You have to do the same thing here," adding, "You're talking about 42 million people and you can federalize it - don't leave it up to the states."

What's clear is that fraud within the food stamp program remains widespread, with evidence indicating that illegals are exploiting the system. This fraud situation is rampant.

Related:

The Trump administration faces a crucial task: breaking the cycle of government dependency by creating real pathways toward personal responsibility, self-reliance, and economic opportunity.

https://www.zerohedge.com/personal-finance/700000-ineligible-snap-recipients-purged-after-usda-uncovers-widespread-food-stamp

HHS Orders State Medicaid Programs to Help Find Illegal Immigrants

 The Trump administration has ordered states to investigate certain individuals enrolled in Medicaid to determine whether they are ineligible because of their immigration status, with five states reporting they've together received more than 170,000 names -- an "unprecedented" step by the federal government that ensnares the state-federal health program in the president's immigration crackdown.

Advocates say the push burdens states with duplicative verification checks and could lead people to lose coverage just for missing paperwork deadlines. But the administrator of the Centers for Medicare & Medicaid Services (CMS), Mehmet Oz, MD, said in a post on the social platform X on Oct. 31 that more than $1 billion "of federal taxpayer dollars were being spent on funding Medicaid for illegal immigrants" in five states and Washington, D.C.

Medicaid's overall spending topped $900 billion in fiscal year 2024.

It wasn't clear from Oz's statement or an accompanying video over what period the spending happened, and CMS spokespeople did not immediately respond to questions, either for an earlier version of this article or after Oz's statement was posted.

Only U.S. citizens and some lawfully present immigrants are eligible for Medicaid, which covers low-income and disabled people, and the closely related Children's Health Insurance Program. Those without legal status are ineligible for federally funded health coverage, including Medicaid, Medicare, and plans through the Affordable Care Act marketplaces.

At least one state said it disagreed with Oz's comments.

"Our payments for coverage of undocumented individuals are in accordance with state and federal laws," said Marc Williams, a spokesperson for Colorado's Department of Health Care Policy & Financing, which administers the state's Medicaid program. "The $1.5 million number referenced by federal leaders today is based on an incorrect preliminary finding, and has been refuted with supporting data by our Department experts."

In August, CMS began sending states the names of people enrolled in Medicaid that the agency suspected might not be eligible, demanding state Medicaid agencies check their immigration status.

KFF Health News in October reached out to Medicaid agencies in 10 states. Five provided the approximate number of names they had received from the Trump administration, with expectations of more to come: Colorado had been given about 45,000 names, Ohio 61,000, Pennsylvania 34,000, Texas 28,000, and Utah 8,000. More than 70 million people are enrolled in Medicaid.

Most of those states declined to comment further. Medicaid agencies in California, Florida, Georgia, New York, and South Carolina refused to say how many names they were ordered to review or did not respond.

Oz said in his X post that California had misspent $1.3 billion on care for people not eligible for Medicaid, while Illinois spent $30 million, Oregon $5.4 million, Washington state $2.4 million, Washington, D.C., $2.1 million, and Colorado $1.5 million.

"We notified the states, and many have begun refunding the money," he said. "But what if we had never asked?"

Washington, D.C.'s Medicaid director, Melisa Byrd, said CMS had identified administrative expenses for the district program that covers people regardless of immigration status that should not have been billed to the federal government and her agency has already fixed some of those areas. "We run a big program that is very complex and when mistakes or errors happen, we fix them," she said.

The program plans to pay $654,014 back to CMS by mid-November.

All five states, plus Washington, D.C., are led by Democrats, and President Donald Trump didn't win any of them in the 2024 election.

In recent days, Deputy HHS Jim O'Neill began posting pictures on X of people he said are convicted criminals living in the U.S. without authorization who had received Medicaid benefits.

O'Neill could not be reached for comment.

As part of the administration's crackdown on people in the U.S. without authorization, Trump in February directed federal agencies to take action to ensure they are not obtaining benefits in violation of federal law.

In June, advisers to HHS Secretary Robert F. Kennedy Jr. ordered CMS to share information about Medicaid enrollees with the Department of Homeland Security, drawing a lawsuit by some states alarmed that the administration would use the information for its deportation campaign against unauthorized residents.

In August, a federal judge ordered HHS to stop sharing the information with immigration authorities.

State Medicaid agencies use databases maintained by the Social Security Administration and Department of Homeland Security to verify enrollees' immigration status.

If states need to go back to individuals to reverify their citizenship or immigration status, it could lead some to fall off the rolls unnecessarily -- for example, if they don't see a letter requesting paperwork or fail to meet a deadline to respond.

"I am not sure that evidence suggests there really is a need for this" extra verification, said Marian Jarlenski, PhD, MPH, a health policy professor at the University of Pittsburgh School of Public Health.

Oz made clear that the Trump administration disagrees.

"Whether willful or not, the states' conduct highlights a terrifying reality: American taxpayers have been footing the bill for illegal immigrants' Medicaid coverage, despite many Democrats and the media insisting otherwise," Oz said in his X post.

In an August press release, CMS said it would ask states to verify eligibility for enrollees whose immigration status could not be confirmed via federal databases. "We expect states to take quick action and will monitor progress on a monthly basis," the agency said.

Oz noted in his post that federal law "does permit states to use Medicaid dollars for emergency treatment, regardless of patients' citizenship or immigration status," and that states can "legally build Medicaid programs for illegal immigrants using their own state tax dollars, so long as no federal tax dollars are used."

The states Oz mentioned all run their own such programs.

The verification checks create an added burden for state Medicaid agencies that are already busy preparing to implement the tax and policy law Trump signed in July. The measure, which Republicans call the One Big Beautiful Bill Act, makes many changes to Medicaid, including adding a work requirement in most states starting by 2027. The law also requires most states to more frequently check the eligibility of many adult Medicaid enrollees -- at least twice a year.

Brandon Cwalina, a spokesperson for the Pennsylvania Department of Human Services, which runs Medicaid in the state, said the state already requires every Medicaid applicant to verify their citizenship or, where applicable, their eligible immigration status.

However, he said, the directive issued by CMS "constitutes a new process, and DHS is carefully reviewing the list in order to take appropriate actions."

Oz did not name Pennsylvania, which Trump won in 2024, in his post.

If a lawful resident does not have a Social Security number, the state confirms their legal status by checking a database from Homeland Security, as well as verifying specific immigration documents, he said.

Other state Medicaid agencies said they also needed to regroup before reaching out to enrollees.

"Our teams just received this notice and are working through a process by which we will perform these reviews," Jennifer Strohecker, then Utah's Medicaid director, told a state advisory board in August.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF

https://www.medpagetoday.com/publichealthpolicy/medicaid/118276

Year in Review: Multiple Myeloma

 News involving the treatment of multiple myeloma this year was highlighted by talk of a potential cure with a single infusion of a chimeric antigen receptor (CAR) T-cell therapy, new FDA approvals (including a drug once pulled from the market), and trials demonstrating efficacy and safety of therapies adapted for older, frail patients.

Potential Cure?

post-hoc analysis of the CARTITUDE-1 trial presented at this year's annual meeting of the American Society of Clinical Oncology led to talk that a single infusion of the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel, Carvykti) offered the "potential of cure" for patients with heavily pretreated relapsed/refractory multiple myeloma.

Among 97 treated patients, 45 were still alive and in long-term follow-up, with a median overall survival (OS) of 60.7 months, reported Peter Voorhees, MD, of the Wake Forest University School of Medicine in Charlotte, North Carolina.

Moreover, 32 patients were alive and progression-free without any further anti-myeloma treatment 5 or more years after treatment with cilta-cel. Of these progression-free patients, 12 from a single center with serial minimal residual disease (MRD) assessments were all MRD-negative and imaging-negative at year 5 or later after cilta-cel without additional therapy.

These results suggest "a potential cure, or at bare minimum, unprecedented durability of complete response," Voorhees said.

Blenrep Completes Comeback

After an odyssey lasting half a decade, the FDA in October once again approved belantamab mafodotin (Blenrep), this time in combination with bortezomib (Velcade) and dexamethasone (BVd) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug.

This approval came 3 years after the drug was pulled from the market over concerns about its efficacy. It was originally granted accelerated approval in 2020 for the treatment of adults with relapsed or refractory disease who had received at least four prior therapies.

The FDA's latest action was based on results from the DREAMM-7 trial, which showed patients treated with the belantamab-based BVd combination had significantly improved progression-free survival (PFS) and OS compared with those who received a combination of daratumumab (Darzalex) plus bortezomib and dexamethasone.

BVd overcame various concerns raised by the FDA's Oncologic Drugs Advisory Committee (ODAC) in July, including ocular toxicities with belantamab mafodotin. ODAC ultimately voted that the risks with the B-cell maturation antigen (BCMA)-targeted agent outweighed the benefits for two proposed indications.

While belantamab mafodotin was approved as part of the BVd combination, it failed to pass muster with the agency in combination with pomalidomide (Pomalyst) and dexamethasone.

The ocular toxicity issue earned belantamab a risk evaluation and mitigation strategy (REMS) from the FDA, as well as a boxed warning.

Other FDA News

The FDA in July granted accelerated approval to linvoseltamab (Lynozyfic) for relapsed/refractory multiple myeloma after at least four prior lines of therapy.

The BCMA-directed bispecific antibody is indicated for adults who have already received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The prescribing information for linvoseltamab includes a boxed warning for cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity, and the product will only be available through a REMS program.

Approval of the bispecific T-cell engager was based on results from LINKER-MM1, a phase I/II trial of 80 patients in which linvoseltamab induced objective responses in 70%, with 45% achieving a complete response or better.

Earlier this year, the FDA's ODAC agreed that results from the phase III AQUILA trial provided sufficient evidence of a favorable risk-benefit profile for subcutaneous daratumumab (Darzalex Faspro) in high-risk smoldering myeloma.

If approved, the drug would be the first therapy available to delay progression from smoldering to active myeloma in high-risk patients.

Wins for Older, Frail Patients

Results from the phase II REST trial showed that a modified version of a regimen combining the anti-CD38 monoclonal antibody isatuximab (Sarclisa) with bortezomib, lenalidomide (Revlimid), and limited dexamethasone was safe and effective for older multiple myeloma patients ineligible for autologous hematopoietic stem cell transplantation.

The study, published in Lancet Haematology, found that among 51 patients ages 70 to 88, MRD-negative complete response was observed in 37%, with an overall response rate of 100% and complete response or better in 47%, while 82% had a very good partial response or better.

Median PFS was not reached, while the 12-month PFS rate was 86%. The 12-month OS rate was 90%.

Moreover, the authors said that the modified regimen appeared to mitigate the risk of increased toxicity -- including infection -- that might be expected with the full regimen.

In another trial published in Lancet Oncology, a dexamethasone-sparing regimen involving lenalidomide and the anti-CD38 drug daratumumab was shown to be safe and effective in older, frail patients with newly diagnosed myeloma.

Among 295 patients, median PFS reached 53.4 months for those assigned to lenalidomide-daratumumab plus dexamethasone limited to just the first two cycles of treatment, as compared with 22.5 months for a control group that received lenalidomide plus continued dexamethasone (HR 0.51, 95% CI 0.37-0.70, P<0.0001).

The regimen did not lead to an increased risk of infections, including pneumonia, suggesting a dexamethasone-sparing strategy can mitigate toxicity risks while maintaining the benefits of anti-CD38 antibody therapy.

A study presented at the annual meeting of the International Myeloma Society showed that a modified daratumumab-based combination achieved encouraging results in an older population of transplant-ineligible patients with newly diagnosed multiple myeloma.

The overall response rate following induction therapy with daratumumab, lenalidomide, ixazomib (Ninlaro), and dexamethasone (D-RId) was 92.4%, including a very good partial response or better rate of 69.6% and a complete response or better rate of 22.8% in 79 evaluable patients, reported Andrew J. Yee, MD, of Massachusetts General Hospital Cancer Center in Boston.

After 12 cycles of D-RId, the 12-month PFS and OS rates were 92% and 93.6%, respectively, "which I believe are favorable outcomes for this transplant-ineligible patient population," Yee said.

Yee and colleagues modified D-RId in the trial by reducing the initial lenalidomide dose from 25 mg to 15 mg to improve tolerability and by replacing bortezomib with the oral proteasome inhibitor ixazomib.

Other Multiple Myeloma News in 2025: